Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab
NCT04377295
·
clinicaltrials.gov ↗
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Radiation Maculopathy
Interventions
DRUG:
Ranibizumab 0.5Mg/0.05Ml Oph Inj
Sponsor
Federico II University